Research ArticleOpioid Stewardship

Suboxone: Rationale, Science, Misconceptions

Jennifer R. Velander
Ochsner Journal March 2018, 18 (1) 23-29;

REFERENCES

  1. ↵
    Centers for Disease Control and Prevention; National Center for Health Statistics. Accidents or unintentional injuries. http://www.cdc.gov/nchs/fastats/accidental-injury.htm. Updated March 17, 2017. Accessed December 19, 2017.
  2. ↵
    1. Katz J.
    Drug deaths in America are rising faster than ever. The New York Times. http://www.nytimes.com/interactive/2017/06/05/upshot/opioid-epidemic-drug-overdose-deaths-are-rising- faster-than-ever.html. Published June 5, 2017. Accessed October 30, 2017.
  3. ↵
    Center for Behavioral Health Statistics and Quality; Substance Abuse and Mental Health Services Administration. Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health. https://www.samhsa.gov/data/sites/default/files/NSDUH-FRR1-2014/NSDUH-FRR1-2014.pdf. Published September 2015. Accessed January 19, 2018.
  4. ↵
    1. Weiss RD.,
    2. Potter JS.,
    3. Fiellin DA.,
    4. et al.
    Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011 12; 68 12: 1238- 1246. doi: 10.1001/archgenpsychiatry.2011.121. pmid:22065255
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Mattick RP.,
    2. Breen C.,
    3. Kimber J.,
    4. Davoli M.
    Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009 7 8; 3: CD002209 doi: 10.1002/14651858.CD002209.pub2. pmid:19588333
    OpenUrlCrossRefPubMed
  6. ↵
    1. Nielsen S.,
    2. Larance B.,
    3. Degenhardt L.,
    4. Gowing L.,
    5. Kehler C.,
    6. Lintzeris N.
    Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database Syst Rev. 2016 5 9; 5: CD011117 doi: 10.1002/14651858.CD011117.pub2. pmid:27157143
    OpenUrlCrossRefPubMed
  7. ↵
    1. Hamid A.
    Drugs in America: Sociology, Economics, and Politics. Gaithersburg, MD: Aspen Publishers, Inc.; 1998: 86.
  8. ↵
    Schaffer Library of Drug Policy. The Harrison Narcotic Act (1914). http://www.druglibrary.org/schaffer/library/studies/cu/cu8.html. Accessed January 19, 2018.
  9. ↵
    1. Dole VP.,
    2. Nyswander M.
    A medical treatment for diacetylmorphine (heroin) addiction. A clinical trial with methadone hydrochloride. JAMA. 1965 8 23; 193: 646- 650. pmid:14321530
    OpenUrlCrossRefPubMed
  10. ↵
    1. Dole VP.
    Methadone maintenance treatment for 25,000 heroin addicts. JAMA. 1971 2 15; 215 7: 1131- 1134. pmid:5107884
    OpenUrlCrossRefPubMed
  11. Pub L No. 91-513, 84 Stat 1236. https://www.gpo.gov/fdsys/pkg/STATUTE-84/pdf/STATUTE-84-Pg1236.pdf. Accessed January 19, 2018.
  12. Pub L No. 93-281, 88 Stat 124. http://www.naabt.org/documents/Narcotic-Addict-Act-1974-public-law-93-281.pdf. Accessed January 19, 2018.
  13. ↵
    1. Gowing L.,
    2. Farrell MF.,
    3. Bornemann R.,
    4. Sullivan LE.,
    5. Ali R.
    Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2011 8 10; 8: CD004145 doi: 10.1002/14651858.CD004145.pub4. pmid:21833948
    OpenUrlCrossRefPubMed
  14. ↵
    1. Tsui JI.,
    2. Evans JL.,
    3. Lum PJ.,
    4. Hahn JA.,
    5. Page K.
    Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Intern Med. 2014 12; 174 12: 1974- 1981. doi: 10.1001/jamainternmed.2014.5416. pmid:25347412
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Jasinski DR.,
    2. Pevnick JS.,
    3. Griffith JD.
    Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry. 1978 4; 35 4: 501- 516. pmid:215096
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    Pub L No. 106-301, 114 Stat 1104. https://www.gpo.gov/fdsys/pkg/PLAW-106publ310/pdf/PLAW-106publ310.pdf. Accessed January 19, 2018.
  17. ↵
    1. Mendelson J.,
    2. Jones RT.
    Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment? Drug Alcohol Depend. 2003 5 21; 70 2 Suppl: S29- S37. pmid:12738348
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    Substance Abuse and Mental Health Services Administration. Buprenorphine training for physicians. http://www.samhsa.gov/medication-assisted-treatment/training-resources/buprenorphine-physician-training. Updated July 7, 2016. Accessed December 19, 2017.
  19. ↵
    US Department of Veterans Affairs; The Management of Substance Use Disorders Work Group. VA/DoD clinical practice guideline for the management of substance use disorders. http://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPGRevised22216.pdf. Published December 2015. Accessed October 10, 2017.
  20. ↵
    1. Kakko J.,
    2. Svanborg KD.,
    3. Kreek MJ.,
    4. Heilig M.
    1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003 2 22; 361 9358: 662- 668. pmid:12606177
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    1. Fudala PJ.,
    2. Bridge TP.,
    3. Herbert S.,
    4. et al.
    Buprenorphine/Naloxone Collaborative Study Group. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003 9 4; 349 10: 949- 958. pmid:12954743
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. Parran TV.,
    2. Adelman CA.,
    3. Merkin B.,
    4. et al.
    Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy. Drug Alcohol Depend. 2010 1 1; 106 1: 56- 60. doi: 10.1016/j.drugalcdep.2009.07.013. pmid:19717249
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. Sordo L.,
    2. Barrio G.,
    3. Bravo MJ.,
    4. et al.
    Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017 4 26; 357: j1550 doi: 10.1136/bmj.j1550. pmid:28446428
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Mitchell SG.,
    2. Gryczynski J.,
    3. Schwartz RP.,
    4. et al.
    Changes in quality of life following buprenorphine treatment: relationship with treatment retention and illicit opioid use. J Psychoactive Drugs. 2015 Apr-Jun; 47 2: 149- 157. doi: 10.1080/02791072.2015.1014948. pmid:25950595
    OpenUrlCrossRefPubMed
  25. ↵
    1. Norton BL.,
    2. Beitin A.,
    3. Glenn M.,
    4. DeLuca J.,
    5. Litwin AH.,
    6. Cunningham CO.
    Retention in buprenorphine treatment is associated with improved HCV care outcomes. J Subst Abuse Treat. 2017 4; 75: 38- 42. doi: 10.1016/j.jsat.2017.01.015. pmid:28237052
    OpenUrlCrossRefPubMed
  26. ↵
    1. Mattick RP.,
    2. Kimber J.,
    3. Breen C.,
    4. Davoli M.
    Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008 4 16; 2: CD002207 doi: 10.1002/14651858.CD002207.pub3. pmid:18425880
    OpenUrlCrossRefPubMed
  27. ↵
    1. Hser YI.,
    2. Saxon AJ.,
    3. Huang D.,
    4. et al.
    Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction. 2014 1; 109 1: 79- 87. doi: 10.1111/add.12333. pmid:23961726
    OpenUrlCrossRefPubMed
  28. ↵
    1. Hser YI.,
    2. Evans E.,
    3. Huang D.,
    4. et al.
    Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction. 2016 4; 111 4: 695- 705. doi: 10.1111/add.13238. pmid:26599131
    OpenUrlCrossRefPubMed
  29. ↵
    1. Thomas CP.,
    2. Fullerton CA.,
    3. Kim M.,
    4. et al.
    Medication-assisted treatment with buprenorphine: assessing the evidence. Psychiatr Serv. 2014 2 1; 65 2: 158- 170. doi: 10.1176/appi.ps.201300256. pmid:24247147
    OpenUrlCrossRefPubMed
  30. ↵
    1. Bell JR.,
    2. Butler B.,
    3. Lawrance A.,
    4. Batey R.,
    5. Salmelainen P.
    Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend. 2009 9 1; 104 1-2: 73- 77. doi: 10.1016/j.drugalcdep.2009.03.020. pmid:19443138
    OpenUrlCrossRefPubMedWeb of Science
  31. ↵
    1. Soyka M.
    New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone. Subst Abuse Rehabil. 2015 1 6; 6: 1- 14. doi: 10.2147/SAR.S45585. pmid:25610012
    OpenUrlCrossRefPubMed
  32. ↵
    1. Schottenfeld RS.,
    2. Chawarski MC.,
    3. Mazlan M.
    Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial. Lancet. 2008 6 28; 371 9631: 2192- 2200. doi: 10.1016/S0140-6736(08)60954-X. pmid:18586174
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    1. Morgan JR.,
    2. Schackman BR.,
    3. Leff JA.,
    4. Linas BP.,
    5. Walley AY.
    Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J Subst Abuse Treat. 2018 2; 85: 90- 96. doi: 10.1016/j.jsat.2017.07.001. pmid:28733097
    OpenUrlCrossRefPubMed
  34. ↵
    1. Crits-Christoph P.,
    2. Markell HM.,
    3. Gibbons MB.,
    4. et al.
    A naturalistic evaluation of extended-release naltrexone in clinical practice in Missouri. J Subst Abuse Treat. 2016 11; 70: 50- 57. doi: 10.1016/j.jsat.2016.07.014. pmid:27692188
    OpenUrlCrossRefPubMed
  35. ↵
    1. Tanum L.,
    2. Solli KK.,
    3. Latif ZE.,
    4. et al.
    Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial. JAMA Psychiatry. 2017 12 1; 74 12: 1197- 1205. doi: 10.1001/jamapsychiatry.2017.3206. pmid:29049469
    OpenUrlCrossRefPubMed
  36. ↵
    1. Lee JD.,
    2. Nunes EV.,
    3. Novo P.,
    4. et al.
    Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2017 11 14 doi: 10.1016/S0140-6736(17)32812-X [Epub ahead of print].
  37. ↵
    1. Digiusto E.,
    2. Shakeshaft A.,
    3. Ritter A.,
    4. O'Brien S.,
    5. Mattick RP.
    NEPOD Research Group. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addiction. 2004 4; 99 4: 450- 460. pmid:15049745
    OpenUrlCrossRefPubMedWeb of Science
  38. ↵
    The American College of Obstetricians and Gynecologists. ACOG Committee Opinion, Number 711. Opioid use and opioid use disorder in pregnancy. https://www.acog.org/Resources-And-Publications/Committee-Opinions/Committee-on-Obstetric-Practice/Opioid-Use-and-Opioid-Use-Disorder-in-Pregnancy. Published August 2017. Accessed October 10, 2017.
  39. ↵
    1. Zedler BK.,
    2. Mann AL.,
    3. Kim MM.,
    4. et al.
    Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child. Addiction. 2016 12; 111 12: 2115- 2128. doi: 10.1111/add.13462. pmid:27223595
    OpenUrlCrossRefPubMed
  40. ↵
    1. Wiegand SL.,
    2. Swortwood MJ.,
    3. Huestis MA.,
    4. Thorp J.,
    5. Jones HE.,
    6. Vora NL.
    Naloxone and metabolites quantification in cord blood of prenatally exposed newborns and correlations with maternal concentrations. AJP Rep. 2016 10; 6 4: e385- e390. pmid:27896019
    OpenUrlPubMed
    1. Debelak K.,
    2. Morrone WR.,
    3. O'Grady KE.,
    4. Jones HE.
    Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data. Am J Addict. 2013 May-Jun; 22 3: 252- 254. doi: 10.1111/j.1521-0391.2012.12005.x. pmid:23617867
    OpenUrlCrossRefPubMed
    1. Wiegand SL.,
    2. Stringer EM.,
    3. Stuebe AM.,
    4. Jones H.,
    5. Seashore C.,
    6. Thorp J.
    Buprenorphine and naloxone compared with methadone treatment in pregnancy. Obstet Gynecol. 2015 2; 125 2: 363- 368. doi: 10.1097/AOG.0000000000000640. pmid:25569005
    OpenUrlCrossRefPubMed
  43. ↵
    1. Jumah NA.,
    2. Edwards C.,
    3. Balfour-Boehm J.,
    4. et al.
    Observational study of the safety of buprenorphine+naloxone in pregnancy in a rural and remote population. BMJ Open. 2016 10 31; 6 10: e011774 doi: 10.1136/bmjopen-2016-011774.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    US Food and Drug Administration. FDA Drug Safety Communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. http://www.fda.gov/Drugs/DrugSafety/ucm575307.htm. Published September 20, 2017. Updated September 26, 2017. Accessed December 19, 2017.
  45. ↵
    1. Woody GE.,
    2. Poole SA.,
    3. Subramaniam G.,
    4. et al.
    Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA. 2008 11 5; 300 17: 2003- 2011. doi: 10.1001/jama.2008.574. pmid:18984887
    OpenUrlCrossRefPubMed
  46. ↵
    1. Carroll KM.,
    2. Weiss RD.
    The role of behavioral interventions in buprenorphine maintenance treatment: a review. Am J Psychiatry. 2017 8 1; 174 8: 738- 747. doi: 10.1176/appi.ajp.2016.16070792. pmid:27978771
    OpenUrlCrossRefPubMed
  47. ↵
    1. Weiss RD.,
    2. Griffin ML.,
    3. Potter JS.,
    4. et al.
    Who benefits from additional drug counseling among prescription opioid-dependent patients receiving buprenorphine-naloxone and standard medical management? Drug Alcohol Depend. 2014 7 1; 140: 118- 122. doi: 10.1016/j.drugalcdep.2014.04.005. pmid:24831754
    OpenUrlCrossRefPubMed
  48. ↵
    1. Rosenblatt RA.,
    2. Andrilla CH.,
    3. Catlin M.,
    4. Larson EH.
    Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Ann Fam Med. 2015 Jan-Feb; 13 1: 23- 26. doi: 10.1370/afm.1735. pmid:25583888
    OpenUrlAbstract/FREE Full Text
  49. ↵
    1. Brooklyn JR.,
    2. Sigmon SC.
    Vermont hub-and-spoke model of care for opioid use disorder: development, implementation, and impact. J Addict Med. 2017 Jul-Aug; 11 4: 286- 292. doi: 10.1097/ADM.0000000000000310. pmid:28379862
    OpenUrlCrossRefPubMed
    1. LaBelle CT.,
    2. Han SC.,
    3. Bergeron A.,
    4. Samet JH.
    Office-based opioid treatment with buprenorphine (OBOT-B): statewide implementation of the Massachusetts collaborative care model in community health centers. J Subst Abuse Treat. 2016 1; 60: 6- 13. doi: 10.1016/j.jsat.2015.06.010. pmid:26233698
    OpenUrlCrossRefPubMed
    1. Komaromy M.,
    2. Duhigg D.,
    3. Metcalf A.,
    4. et al.
    Project ECHO (extension for community healthcare outcomes): a new model for educating primary care providers about treatment of substance use disorders. Subst Abus. 2016; 37 1: 20- 24. doi: 10.1080/08897077.2015.1129388. pmid:26848803
    OpenUrlCrossRefPubMed
    1. Liebschutz JM.,
    2. Crooks D.,
    3. Herman D.,
    4. et al.
    Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. JAMA Intern Med. 2014 8; 174 8: 1369- 1376. doi: 10.1001/jamainternmed.2014.2556. pmid:25090173
    OpenUrlCrossRefPubMed
    1. Trowbridge P.,
    2. Weinstein ZM.,
    3. Kerensky T.,
    4. et al.
    Addiction consultation services - linking hospitalized patients to outpatient addiction treatment. J Subst Abuse Treat. 2017 8; 79: 1- 5. doi: 10.1016/j.jsat.2017.05.007. pmid:28673521
    OpenUrlCrossRefPubMed
  54. ↵
    1. D'Onofrio G.,
    2. O'Connor PG.,
    3. Pantalon MV.,
    4. et al.
    Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015 4 28; 313 16: 1636- 1644. doi: 10.1001/jama.2015.3474. pmid:25919527
    OpenUrlCrossRefPubMed
  55. ↵
    1. Jones EB.
    Medication-assisted opioid treatment prescribers in federally qualified health centers: capacity lags in rural areas. J Rural Health. 2018 12; 34 1: 14- 22. doi: 10.1111/jrh.12260. pmid:28842930
    OpenUrlCrossRefPubMed
  56. ↵
    Louisiana Commission on Preventing Opioid Abuse. The Opioid Epidemic: Evidence-Based Strategies Legislative Report, April 2017. http://www.pharmacy.la.gov/assets/docs/Public_Library/LCPOA_FinalReportPublic_2017-0331.pdf. Published March 31, 2017. Accessed October 10, 2017.
  57. ↵
    1. Netherland J.,
    2. Botsko M.,
    3. Egan JE.,
    4. et al.
    BHIVES Collaborative. Factors affecting willingness to provide buprenorphine treatment. J Subst Abuse Treat. 2009 4; 36 3: 244- 251. doi: 10.1016/j.jsat.2008.06.006. pmid:18715741
    OpenUrlCrossRefPubMedWeb of Science
  58. ↵
    Substance Abuse and Mental Health Services Administration. Treatments for substance use disorders. https://www.samhsa.gov/treatment/substance-use-disorders. Updated August 9, 2016. Accessed December 19, 2017.
  59. ↵
    Hazelden Betty Ford Foundation. COR-12™ opioid treatment program: making a difference in Oregon. http://www.hazeldenbettyford.org/articles/2016-news/cor-12-opioid-treatment-making-a-difference. Published December 1, 2016. Accessed December 19, 2017.
  60. ↵
    1. Monico LB.,
    2. Gryczynski J.,
    3. Mitchell SG.,
    4. Schwartz RP.,
    5. O'Grady KE.,
    6. Jaffe JH.
    Buprenorphine treatment and 12-step meeting attendance: conflicts, compatibilities, and patient outcomes. J Subst Abuse Treat. 2015 10; 57: 89- 95. doi: 10.1016/j.jsat.2015.05.005. pmid:25986647
    OpenUrlCrossRefPubMed
  61. ↵
    1. Lofwall MR.,
    2. Walsh SL.
    A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. J Addict Med. 2014 Sep-Oct; 8 5: 315- 326. doi: 10.1097/ADM.0000000000000045. pmid:25221984
    OpenUrlCrossRefPubMed
  62. ↵
    1. Bazazi AR.,
    2. Yokell M.,
    3. Fu JJ.,
    4. Rich JD.,
    5. Zaller ND.
    Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users. J Addict Med. 2011 9; 5 3: 175- 180. doi: 10.1097/ADM.0b013e3182034e31. pmid:21844833
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section